A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes

Lee, Nicole, Pennay, Amy, Hester, Robert, McKetin, Rebecca, Nielsen, Suzi and Ferris, Jason (2013) A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes. Drug and Alcohol Review, 32 1: 88-95. doi:10.1111/j.1465-3362.2012.00473.x


Author Lee, Nicole
Pennay, Amy
Hester, Robert
McKetin, Rebecca
Nielsen, Suzi
Ferris, Jason
Title A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes
Journal name Drug and Alcohol Review   Check publisher's open access policy
ISSN 0959-5236
1465-3362
Publication date 2013-01-01
Year available 2012
Sub-type Article (original research)
DOI 10.1111/j.1465-3362.2012.00473.x
Open Access Status DOI
Volume 32
Issue 1
Start page 88
End page 95
Total pages 8
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell
Collection year 2013
Language eng
Formatted abstract
Introduction and Aims: There are no medications approved for the treatment of methamphetamine withdrawal. Wake-promoting agent modafinil has recently been proposed as a viable option. This paper reports on the results of a pilot study that tested the feasibility of modafinil in an inpatient withdrawal setting during acute methamphetamine withdrawal.

Design and Methods: In a double-blind, randomised, placebo-controlled study, 19 methamphetamine dependent participants received modafinil (n=9) or placebo (n=10) daily for 7days (200mg for the first 5days and 100mg on days 6 and 7). Primary outcomes were retention in treatment and severity of withdrawal symptoms. Secondary outcomes were methamphetamine craving, sleep and physiological outcomes.

Results: There were no significant differences between groups on retention in treatment, withdrawal severity, craving, sleep or physiological outcomes. There were no adverse events or side-effects reported.

Conclusions: Modafinil was found to be tolerable and well accepted by methamphetamine users and feasible for short-term inpatient withdrawal, but the sample was too small to detect treatment effects. Larger trials are needed to establish efficacy.
Keyword Methamphetamine
Modafinil
Withdrawal
Randomised controlled trial
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article first published online: 27 May 2012.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Institute for Social Science Research - Publications
Official 2013 Collection
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 17 Feb 2013, 11:05:05 EST by System User on behalf of Institute for Social Science Research